Influenza vaccine: Issues and opportunities

被引：16

作者：

Neuzil, KM

Griffin, MR

Schaffner, W

机构：

[1] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA

[2] Univ Washington, Sch Med, Div Infect Dis, Seattle, WA 98195 USA

[3] VA Puget Sound Hlth Care Syst, Seattle, WA USA

[4] Vanderbilt Univ, Sch Med, Div Gen Internal Med, Nashville, TN 37232 USA

[5] Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN 37232 USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2001年 / 15卷 / 01期

关键词：

D O I：

10.1016/S0891-5520(05)70271-3

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Several recent developments offer opportunities to improve the diagnosis, treatment, and prevention of influenza. Rapid diagnostic tests assist in selecting patients for antiviral therapy and avoid some antibiotic use. The neuraminidase inhibitors now offer therapeutic options with potentially fewer side effects than the traditional drugs, albeit at greater cost. Inactivated influenza vaccine is now recommended annually for all persons aged 50 and older and younger adults and children (aged 6 months and older) who have underlying risk factors for the severe complications of influenza. This includes pregnant women who are in their second or third trimesters during influenza season.

引用

页码：123 / +

页数：20

共 84 条

[1]

[Anonymous], 1999, MMWR Recomm Rep, V48, P1

[2]

[Anonymous], 2000, MMWR Recomm Rep, V49, P1

[3]

[Anonymous], 1999, MED LETT DRUGS THER, V41, P29

[4] IMPACT OF EPIDEMIC TYPE A INFLUENZA IN A DEFINED ADULT-POPULATION [J].